{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:15:28Z","timestamp":1766391328165,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.leukres.2022.106966","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:04:39Z","timestamp":1665637479000},"page":"106966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)"],"prefix":"10.1016","volume":"123","author":[{"given":"Haris","family":"Hatic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shealeigh","family":"Inselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Inselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuhya","family":"Kommalapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Harsha","family":"Tella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-2424","authenticated-orcid":false,"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106966_bib1","article-title":"Connect MM Registry as a national reference for United States multiple myeloma patients","author":"Ailawadhi","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.leukres.2022.106966_bib2","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2022.106966_bib3","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2022.106966_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2022.106966_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.leukres.2022.106966_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106966_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004023","article-title":"Early versus deferred treatment for early stage multiple myeloma","author":"He","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.leukres.2022.106966_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106966_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2022.106966_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-143340","article-title":"Retrospective analysis of the relationship between time to anti-resorptive therapy and incidence of skeletal related events in patients with multiple myeloma","volume":"136","author":"Hughes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106966_bib11","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106966_bib12","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3109\/10428194.2016.1170828","article-title":"Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity","volume":"57","author":"Costa","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2022.106966_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15224","article-title":"Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas","volume":"181","author":"Olszewski","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106966_bib14","unstructured":"Surgeons ACo. National Cancer Database 1996\u20132019."},{"key":"10.1016\/j.leukres.2022.106966_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.100","article-title":"Prevalence, incidence and survival of smoldering multiple myeloma in the United States","volume":"6","author":"Ravindran","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2022.106966_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.leukres.2022.106966_bib17","article-title":"Time to initial cancer treatment in the United States and association with survival over time: an oservational study","volume":"14","author":"Khorana","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2022.106966_bib18","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/bjc.2015.48","article-title":"Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? systematic review","volume":"112","author":"Neal","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2022.106966_bib19","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1080\/10428194.2017.1422863","article-title":"The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma","volume":"59","author":"Phipps","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2022.106966_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.19.00309","article-title":"Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care","author":"Kumar","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.leukres.2022.106966_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clml.2012.06.008","article-title":"Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry","volume":"12","author":"Offidani","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2022.106966_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2012.09124.x","article-title":"Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups","volume":"158","author":"Ailawadhi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106966_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the cooperative Group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2022.106966_bib24","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2022.106966_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/10428190902741471","article-title":"Diagnostic delay and complications for older adults with multiple myeloma","volume":"50","author":"Friese","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2022.106966_bib26","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1080\/03007995.2016.1226166","article-title":"A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma","volume":"32","author":"Yusuf","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.leukres.2022.106966_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2022.106966_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1200\/EDBK_200841","article-title":"Global approaches in myeloma: critical trials that may change practice","volume":"38","author":"Moreau","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.leukres.2022.106966_bib29","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/jgs.14833","article-title":"Exclusion of elderly people from randomized clinical trials of drugs for ischemic heart disease","volume":"65","author":"Bourgeois","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.leukres.2022.106966_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00432-017-2529-9","article-title":"Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries","volume":"144","author":"Augustin","year":"2018","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106966_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1634\/theoncologist.2014-0093","article-title":"Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry","volume":"19","author":"Hamaker","year":"2014","journal-title":"Oncologist"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:10Z","timestamp":1758934990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622003423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":31,"alternative-id":["S0145212622003423"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106966","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106966"}}